Interleukins Patents (Class 435/69.52)
-
Patent number: 7803564Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-?. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: GrantFiled: September 26, 2007Date of Patent: September 28, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Samantha J. Busfield, David P. Gearing
-
Patent number: 7767199Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.Type: GrantFiled: October 5, 2006Date of Patent: August 3, 2010Assignee: ZymoGenetics, Inc.Inventor: Jeffrey D. Meyer
-
Patent number: 7767793Abstract: DNA encoding SIGIRR polypeptides and methods for using the encoded polypeptides are disclosed.Type: GrantFiled: October 30, 2007Date of Patent: August 3, 2010Inventor: John Ernest Sims
-
PLASMID FOR EXPRESSING THIOREDOXIN FUSION PROTEIN AND METHOD FOR PRODUCING TARGET PROTEIN USING SAME
Publication number: 20100184146Abstract: The present invention provides a plasmid for expressing a thioredoxin fusion protein comprising thioredoxin as a fusion partner, an E. coli cell transformed with the plasmid, and an efficient method for producing a target protein using the E. coli cell. The method according to the present invention can easily remove thioredoxin from thioredoxin fusion protein, so that can produce a target protein of interest in pure and large quantities in the field of medicine and bioengineering.Type: ApplicationFiled: August 24, 2009Publication date: July 22, 2010Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Hee-Chul Ahn, Hyung Jun Ahn, Dong Yun Shin, Jong Soo Lim, Dae-Ro Ahn -
Patent number: 7759092Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: GrantFiled: August 7, 2009Date of Patent: July 20, 2010Assignee: ZymoGenetics, LLCInventors: Bruce L. Zamost, Robert M. Dedinsky
-
Patent number: 7758853Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.Type: GrantFiled: August 12, 1999Date of Patent: July 20, 2010Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Haruki Okamura, Tadao Tanimoto, Kakuji Torigoe, Toshi Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto
-
Patent number: 7745176Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.Type: GrantFiled: October 5, 2006Date of Patent: June 29, 2010Assignee: ZymoGenetics, Inc.Inventors: Bruce L. Zamost, Douglas C. Covert
-
Publication number: 20100159465Abstract: The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyses. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.Type: ApplicationFiled: December 4, 2009Publication date: June 24, 2010Inventors: JUNG-HOON SOHN, JUNG-HOON BAE, HYUN-JIN KIM, KWANG-MOOK LIM, SEUNG LI KIM
-
Publication number: 20100129318Abstract: The present invention relates to at least one novel cynomolgus IL-13 muteins (Mut-IL-13) proteins, antibodies, including isolated nucleic acids that encode at least one Mut-IL-13 protein or antibody, Mut-IL-13 vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: October 12, 2007Publication date: May 27, 2010Applicant: CENTOCOR ORTHO BIOTECH INC.Inventors: Karyn O'Neil, Leslee Conrad, Dusti Fisher
-
Publication number: 20100104531Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: ApplicationFiled: October 1, 2009Publication date: April 29, 2010Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7704710Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: May 7, 2008Date of Patent: April 27, 2010Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 7705128Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-1?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: July 1, 2008Date of Patent: April 27, 2010Assignee: Schering CorporationInventor: Jacqueline C. Timans
-
Publication number: 20100086516Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed. Methods of medical treatment using such molecules and antagonists of the IL-13/IL-13R interaction are also provided.Type: ApplicationFiled: March 20, 2009Publication date: April 8, 2010Applicants: GENETICS INSTITUTE, LLC, THE JOHNS HOPKINS UNIVERSITYInventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew J. Whitters, Clive Wood, Marsha Wills-Karp
-
Patent number: 7666628Abstract: The present invention relates to the use of a class of genes called oil body protein genes that have unique features. The discovery of these features allowed the invention of methods for the production of recombinant proteins wherein a protein of interest can be easily separated from other host cell components. The invention is further exemplified by methods for exploitation of the unique characteristics of the oil body proteins and oil body genes for expression of polypeptides of interest in many organisms, particularly plant seeds. Said polypeptides may include but are not limited to: seed storage proteins, enzymes, bioactive peptides, antibodies and the like. The invention can also be modified to recover recombinant polypeptides fused to oil body proteins from non-plant host cells. Additionally the invention provides a method of using recombinant proteins associated with seed oil bodies released during seed germination for expression of polypeptides that afford protection to seedlings from pathogens.Type: GrantFiled: January 26, 2004Date of Patent: February 23, 2010Assignee: SemBioSys Genetics Inc.Inventors: Maurice M. Moloney, Gijs Van Rooijen
-
Patent number: 7662590Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 19, 2006Date of Patent: February 16, 2010Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7662589Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: February 16, 2010Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Publication number: 20100021965Abstract: A method is described for the expression of heterologous polypeptides in rodent cells. The method comprises the oriP/EBNA-1 episomal replication and maintenance system of the Epstein-Barr-Virus (EBV). With the stable integration of an EBNA-1-protein expression cassette under the control of a promoter into the genome of a rodent cell an EBNA-1-protein expression in the cells was obtained. The heterologous protein is expressed from an episome comprising an EBV origin of replication and a functional expression cassette of said heterologous protein. The invention further comprises transformed rodent cell lines, a method for the production of a heterologous protein in said cell lines and a kit for the construction of said cell lines.Type: ApplicationFiled: October 26, 2006Publication date: January 28, 2010Inventors: Ulrich Goepfert, Erhard Kopetzki
-
Publication number: 20100003722Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: ApplicationFiled: August 7, 2009Publication date: January 7, 2010Applicant: ZymoGenetics, LLCInventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
-
Publication number: 20090324538Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: ApplicationFiled: May 9, 2008Publication date: December 31, 2009Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 7638305Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: December 29, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Publication number: 20090311725Abstract: The current invention describes a nucleic acid comprising in a 5? to 3? direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5? splice donor site and terminated by a 3? splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.Type: ApplicationFiled: May 15, 2007Publication date: December 17, 2009Inventors: Josef Endl, Erhard Kopetzki, Oliver Ploettner, Ursula Schwarz, Georg Tiefenthaler
-
Patent number: 7629149Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: December 8, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7629148Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: December 8, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Publication number: 20090298055Abstract: The present invention is of a method of producing proteins in mammalian cells using a permanent selection in the absence of cytotoxic drugs. Specifically, the present invention can be used to produce large quantities of highly pure human proteins which are suitable for pharmaceutical applications.Type: ApplicationFiled: November 28, 2005Publication date: December 3, 2009Applicant: Applied Research Systems ARS Holding S.A.Inventors: Yehuda Assaraf, Lilac Rothem
-
Patent number: 7625720Abstract: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: November 27, 2006Date of Patent: December 1, 2009Assignee: Schering CorporationInventors: Daniel M. Gorman, J. Fernando Bazan, Robert A. Kastelein, Gerard Zurawski
-
Publication number: 20090269811Abstract: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.Type: ApplicationFiled: July 1, 2009Publication date: October 29, 2009Applicant: Genentech, Inc.Inventors: Audrey Goddard, Guohua James Pan
-
Patent number: 7608428Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: October 27, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7608427Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: October 27, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Publication number: 20090253179Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.Type: ApplicationFiled: March 17, 2009Publication date: October 8, 2009Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Zhengxing Qu, Chien-Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang, Diane Nordstrom
-
Patent number: 7598058Abstract: This invention provides nucleic acid molecules encoding mutant human interleukin 13 molecules showing varying specificity for the restricted (IL4 independent) IL13 receptor. The mutant hIL13 molecules include those made by substituting the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Some of the mutants retain the ability to bind and cause signaling through IL13 receptors, while other mutants do not.Type: GrantFiled: August 24, 2004Date of Patent: October 6, 2009Assignee: Penn State Research FoundationInventors: Waldemar Debinski, Jeffrey P. Thompson
-
Patent number: 7595174Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 29, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Publication number: 20090239258Abstract: Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: ApplicationFiled: May 22, 2009Publication date: September 24, 2009Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
-
Publication number: 20090239262Abstract: The present disclosure provides an affinity polypeptide for the purification of a recombinant biologically active protein or polypeptide. Further, the present disclosure provides a fusion recombinant protein or polypeptide wherein the fusion recombinant protein comprises of at least two components, a biologically active polypeptide or protein or protein of interest and the affinity polypeptide. The biologically active polypeptide may be linked directly or indirectly to the affinity polypeptide by covalent binding. The present disclosure provides a recombinant expression vector for the producing said fusion recombinant protein in host cells. Further, the present disclosure provides an improved method of purification of recombinant protein from the host cells. Further, the disclosure provides a method of purification of the recombinant biologically active polypeptide or protein by immobilized metal ion chelating chromatography.Type: ApplicationFiled: February 7, 2007Publication date: September 24, 2009Inventors: Laxmi Srinivas Rao, Shrikant Mishra, Monsur Ahmed Borbhuiya, Deepa Mhatre, Priti Thakur
-
Publication number: 20090233333Abstract: The present invention relates to methods of preventing glyconoylation of polypeptides produced in micororganisms.Type: ApplicationFiled: March 4, 2004Publication date: September 17, 2009Applicant: FRANCE TELECOMInventor: ALAN R Gardner
-
Patent number: 7588918Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 15, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7588919Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 15, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7582450Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 1, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Publication number: 20090214513Abstract: The present invention features mammalian expression systems with improved production yields, and method of using these systems to produce desired proteins. In one embodiment, the expression systems of the present invention comprise genetically-engineered mammalian host cells cultured in a medium that contains an effective amount of heparin or heparin-like molecules. The presence of heparin or heparin-like molecules significantly increases protein production by the cultured cells. The present invention also features the use of constitutively-active components of FGFR-I-mediated signal transduction pathways to improve protein production by cultured mammalian cells. Co-expression of such a component with a protein of interest markedly increases the production yield of the protein of interest.Type: ApplicationFiled: April 20, 2006Publication date: August 27, 2009Applicant: WyethInventors: Xiaotian Zhong, Ronald William Kriz, Mark Lloyd Stahl
-
Publication number: 20090202502Abstract: Methods and reagents for effecting transgene expression in Hepatic Stellate Cells (HSC) comprising a 2.2 kb fragment of the promoter region of the Glial Fibrillary Acidic Protein (GFAP) gene, said construct being up-regulated by pro-fÊbronetic cytokines such as TGF-beta 1 in a dose and time dependent manner, and uses thereof.Type: ApplicationFiled: June 9, 2006Publication date: August 13, 2009Applicant: AGENCY FOR SCIENCE TECHNOLOGY & RESEARCHInventors: Lang Zhuo, Gunter Maubach
-
Publication number: 20090203076Abstract: Compositions and methods for increasing protein production are provided.Type: ApplicationFiled: September 9, 2008Publication date: August 13, 2009Inventors: Alexander V. Kabanov, Valery Alakhov
-
Publication number: 20090170163Abstract: The present invention relates to fusion proteins. The invention specifically relates to compositions and methods of Tf-based fusion proteins that demonstrate a high-level expression of transferrin (Tf)-based fusion proteins by inserting a helical linker between two protein domains.Type: ApplicationFiled: December 19, 2008Publication date: July 2, 2009Applicant: University of Southern CaliforniaInventors: Wei-Chiang Shen, Nurmamet Amet, Xiaoying Chen, Hsin-Fang Lee
-
Patent number: 7544779Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 13, 2006Date of Patent: June 9, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Publication number: 20090142806Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease).Type: ApplicationFiled: August 21, 2008Publication date: June 4, 2009Applicant: WYETHInventors: BEATRIZ M. CARRENO, MARY COLLINS, JILL F. WRIGHT, NEIL M. WOLFMAN, MAYA ARAI, KENNETH JACOBS, ZHIJIAN LU, YONGJING GUO, YONGCHANG QIU
-
Publication number: 20090142855Abstract: The present invention relates to the primate family of cytokines. Provided herein are polynucleotides encoding such polypeptides, and reagents useful for producing the encoded polypeptides in a host source, and for identifying compounds which bind and modulate the activity of the encoded polypeptides. Also provided are reagents useful for the diagnosis or treatment of inflammatory and/or autoimmune related diseases in primates.Type: ApplicationFiled: June 30, 2006Publication date: June 4, 2009Inventors: Wei Tang, Yuxun Wang, Shuhao Zhu
-
Patent number: 7541040Abstract: The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.Type: GrantFiled: February 28, 2002Date of Patent: June 2, 2009Assignees: The United States of America as represented by the Department of Health and Human Serivces, The Regents of the University of Michigan, Office of Technology TransferInventors: Raj K. Puri, Cory M. Hogaboam, Claudia Jakubzick, Steven L. Kunkel
-
Publication number: 20090137005Abstract: The present invention provides for nucleic acids improved for the expression of interleukin-12 (IL-12) in mammalian cells. The invention further provides for methods of expressing IL-12 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-12 sequence.Type: ApplicationFiled: January 12, 2007Publication date: May 28, 2009Applicant: The Government of the United States of America, as a representative by the Secretary of the DepartInventors: Barbara Felber, George N. Pavlakis, Margherita Rosati
-
Patent number: 7534585Abstract: The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.Type: GrantFiled: July 20, 2004Date of Patent: May 19, 2009Assignee: Transgene S.A.Inventor: Stephane Paul
-
Publication number: 20090117618Abstract: The invention relates to an expression system containing one or more nucleic acid(s) comprising at least one nucleic acid for an interleukin 15/Fc (IL-15/Fc) fusion protein, at least one promotor, at least one nucleic acid for a CD5 leader and, where appropriate, at least one nucleic acid for a selectable marker gene; to a nucleic acid comprising the components of the said expression system and to a host cell containing the expression system or the nucleic acid. Furthermore, the invention relates to a process for preparing an IL-15/Fc fusion protein, using the expression system, and to the use of the expression system, the nucleic acid, the host cell or the CD5 leader for expression in host cells.Type: ApplicationFiled: April 13, 2005Publication date: May 7, 2009Inventors: Andreas Herrmann, Ingeborg Dreher, Thomas Moll, Stefanie Zahn
-
Publication number: 20090111765Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.Type: ApplicationFiled: September 14, 2006Publication date: April 30, 2009Inventors: Gunther Hartmann, Veit Hornung
-
Patent number: RE41129Abstract: The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: February 2, 2006Date of Patent: February 16, 2010Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 5117060Abstract: Disclosed is an improved process for the preparation of ketoximes, especially ketoximes derived from branched chain ketones, wherein a ketone is reacted with a hydroxylamine salt in the presence of an alkanol, a heterogeneous base and up to about 5 weight percent, based on the weight of the ketone and alkanol, water.Type: GrantFiled: June 10, 1991Date of Patent: May 26, 1992Assignee: Eastman Kodak CompanyInventor: Jonathan S. Witzeman